The short version
- Why people research itLibido, hormonal signaling and reproductive / sexual function.
- What the evidence isApproved — as a subcutaneous rescue therapy for Parkinson's 'off' episodes, with solid trial data.
- What to watchFainting or a sharp blood pressure drop on standing.
How Apomorphine works
Non-selective dopamine agonist acting centrally at the paraventricular nucleus — it drives erection through the brain rather than through vascular smooth muscle, which is a completely different route from a PDE5 inhibitor.
Start with the name, because it is the most misleading name in the catalog. Apomorphine is made from morphine by an acid-driven rearrangement, and that shared ancestry is the entire connection.
It is not selective, and the lack of selectivity is the point. Jenner 2016 describes apomorphine as a potent, direct and broad-spectrum dopamine agonist activating all dopamine receptor subtypes, with additional affinity for serotonin and α-adrenergic receptors. That separates it cleanly from pramipexole and ropinirole, which are D2/D3-preferring.
- Oral
On the goal map: Central desire — melanocortin & dopaminergic (Libido & sexual function)
Research on Apomorphine4 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Was approved in Europe as Uprima; withdrawn commercially rather than for safety.
Human clinical evidence
Approved — as a subcutaneous rescue therapy for Parkinson's 'off' episodes, with solid trial data. It was also approved as sublingual Uprima for erectile dysfunction in Europe and later withdrawn commercially, having shown efficacy below the PDE5 inhibitors with substantially more nausea.
Correlative data
Limited community use. Where it is used it tends to be by people for whom PDE5 inhibitors did nothing — which is a coherent reason, since the mechanism is unrelated.
How the mechanism reads
A non-selective dopamine agonist acting centrally — despite the name it contains no morphine and has no opioid activity.
MechanisticCentral dopaminergic action on erectile function is a genuinely different mechanism from PDE5 inhibition, which is peripheral and vascular. The same central dopaminergic activity drives the nausea through the chemoreceptor trigger zone, which is why it never displaced the PDE5 drugs.
Mechanistic
Sources
- U.S. Food and Drug Administration. APOKYN (apomorphine hydrochloride injection), for subcutaneous use - full prescribing information (NDA 021264).. FDA approved labeling, revision 2025
- U.S. Food and Drug Administration. KYNMOBI (apomorphine hydrochloride) sublingual film - full prescribing information (NDA 210875).. FDA approved labeling, revision 2022
- Jenner P. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. Parkinsonism Relat Disord 2016 · PMID 27979722
- Dewey RB Jr. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001 · PMID 11559309
- Katzenschlager R. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018 · PMID 30055903
- Olanow CW. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 2020 · PMID 31818699
- Dula E. Eur Urol 2001 · PMID 11464037
- Agbo F. Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and OFF Episodes. Neurol Ther 2021 · PMID 33991326
Apomorphine safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Taking ondansetron, granisetron or another 5-HT3 antagonist, which has caused profound hypotension with apomorphine.
- Low blood pressure, severe heart disease or a prolonged QT interval.
- Sulfite allergy, for injectable forms.
- Psychosis or dementia, since it is a potent dopamine agonist.
- Severe liver or kidney impairment, as apomorphine is cleared by both routes.
What’s expected
- Nausea, because the dopamine receptors at the vomiting center are hit first.
- Yawning, sweating and dizziness in the first minutes.
- Erectile response driven centrally rather than through blood vessels.
Watch for
- Fainting or a sharp blood pressure drop on standing.
- Sudden sleep onset without warning.
- An erection that will not go down.
Labs that tell you it’s working
- Prolactin: dopamine agonism suppresses it, so a low value confirms receptor engagement.
- Comprehensive Metabolic Panel: liver and kidney handling.
- Magnesium: low magnesium raises the risk of QT problems.
Non-selective D1 and D2 dopamine agonist acting in the paraventricular nucleus; hypotension and emesis follow from receptor spread. PMID 27979722 PMID 11559309
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “Low T? Rule Out the Reversible Causes First” panel, explained
Apomorphine FAQ4 common questions
- Is Apomorphine approved for human use?
- No. Apomorphine is a research compound.
- What is Apomorphine researched for?
- Libido, hormonal signaling and reproductive / sexual function.
- Which labs show whether it's doing anything?
- Prolactin; Comprehensive Metabolic Panel; Magnesium: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Apomorphine: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



